MHRA Performance Data
Updated 19 May 2025
© Crown copyright 2025
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/mhra-performance-data/mhra-performance-data
Overview
Our 2024/25 business plan gave a commitment to our focus being the optimisation of our service delivery for customers. It introduced key performance indicators (KPIs) and a corporate objective to enhance the transparency and accessibility of our performance data. Here we provide the MHRA performance data for April 2025 for each KPI.
Our aim is to help applicants with decision making, based on our performance data, and to ensure greater accountability for our service delivery.
How we present performance data
We publish each KPI in full, together with a percentage to indicate performance in the last month, and year to date (YTD) averages where data is available.
We provide information on the target timeline to complete a specific regulatory function and the current average timeline. Additional context is provided to signpost applicants to additional useful information.
April performance data
As the new reporting year began on 1 April 2025, our year-to-date performance data currently reflects only this month’s figures.
We continue to report consistent performance against agreed key performance indicators in MHRA’s statutory functions: licence applications for innovative and established medicines, variations to licences, and manufacturing and distribution authorisations.
Our priority is to maintain performance to predictable and statutory timeframes. We will continue to publish monthly updates providing applicants with transparent information on expected timescales.
Other key highlights for April 2025 include:
Clinical trials and investigations: Our data show that 100% of clinical trials and investigations applications continue to be handled within statutory timescales. Combined Review approval time with the Health Research Authority is now at 60 days or less for all trials, with an average time for Combined Review determination (including questions raised) of 40 days in April.
Vaccine Batches and Blood Product Batches: From April 2025 we will no longer provide data distinguishing between COVID-19 and other vaccine types.
Medicines licensing applications: From April 2025 we will no longer provide data relating to backlog clearance, as on 31 March 2025, we cleared all backlogs related to licence applications for innovative and established medicines. All new national licence applications are being assessed within our target of 210 days: with an average timescale of 166 days in March.
Variations: From April 2025 we will no longer provide data relating to backlog clearance, as on 31 March 2025, we cleared all backlogs relating to variations to licences.
Reports of Adverse Incidents: From April 2025, the performance data for responding to reports of adverse incidents are measured against new KPIs. We have streamlined reporting from four separate elements to one to help provide greater accuracy and predictability of our service delivery.
Scientific advice: From April 2025, the performance data for scientific advice requests are measured against new KPIs. These new indicators have been introduced help provide greater transparency, accuracy and predictability of our service delivery.
More resources are now available to help clear scientific advice requests and we expect further signs of positive impact to be reported in our data for future months. We will sustain this effort over the coming months as part of our wider work to further develop and enhance our scientific advice services.
Find out about our work to overhaul the Scientific Advice service at MHRA.
Clinical Trial Authorisation (CTA) and Clinical Investigation applications
| Key Performance Indicator (KPI) | KPI Performance April 2025 | KPI Performance 2025/26 YTD |
|---|---|---|
| 1. We will assess 95% of all initial Clinical Trial Authorisation (CTA) and Clinical Investigation applications within their category’s statutory timeline. | 100% | 100% |
Clinical Trials
| Regulatory Service | Target (days) | Last month average (days) | Notes |
|---|---|---|---|
| Initials | 30 | 28 | The MHRA contribute performance data to the UK Clinical Research Delivery Performance Indicators Report New clinical trials regulations have now been signed into law. The new regulations will take full effect from 28 April 2026, following the 12-month implementation period. |
| Amendments | 35 | 31 |
Clinical Investigations
| Regulatory Service | Target (days) | Last month average (days) |
|---|---|---|
| Initials | 60 | 41 |
| Amendments | 21 | 5 |
Vaccine batches and blood product batches
| Key Performance Indicator (KPI) | KPI Performance April 2025 | KPI Performance 2025/26 YTD |
|---|---|---|
| 2. We will certify 95% of vaccine batches within 43 days and 95% of blood product batches within 15 days of submission. | 99% | 99% |
| Regulatory Service | Target (days) | Last month average (days) | Notes |
|---|---|---|---|
| Batch Certification: | The timescale for batch certification starts once the MHRA has receipt of all components required for the testing, not receipt of the first component. | ||
| Vaccines | 43 | 4 | |
| Blood Products | 15 | 7 |
Medicines licence applications via the national route
| Key Performance Indicator (KPI) | KPI Performance April 2025 | KPI Performance 2025/26 YTD |
|---|---|---|
| 3. We will determine 95% of medicines licence applications within 210 days via the national route. | 100% | 100% |
| Regulatory Service | Target (days) | Last month average (days) | Notes |
|---|---|---|---|
| Licensing applications: National (Established) | 210 | 166 | Find out more about our work to embed improvements in processing medicines licensing applications in standard working practice. |
| Licensing applications: National (new active substance; NAS) | 210 | 184 |
Medicines licence applications through the International Recognition Procedure
| Key Performance Indicator (KPI) | KPI Performance April 2025 | KPI Performance 2025/26 YTD |
|---|---|---|
| 4. We will determine 95% of medicines licence applications within 60 days via recognition Route A and within 110 days via Route B through the International Recognition Procedure (IRP). | 100% | 100% |
| Regulatory Service | Target (days) | Last month average (days) | Notes |
|---|---|---|---|
| Licensing applications: International Recognition Procedure (IRP) | |||
| Route A | 60 | 57 | |
| Route B | 110 | 105 |
National variations
| Key Performance Indicator (KPI) | KPI Performance April 2025 | KPI Performance 2025/26 YTD |
|---|---|---|
| 5. We will determine 95% of all national variations within their category’s statutory timeline. | 97% | 97% |
| Regulatory Service | Target (days) | Last month average (days) |
|---|---|---|
| Variations | ||
| Type 1b | 30 | 19 |
| Type 2 | 90 | 34 |
| Safety Variations | ||
| Type 1b | 30 | 16 |
| Type 2 | 90 | 46 |
Manufacturing and distribution authorisations
| Key Performance Indicator (KPI) | KPI Performance April 2025 | KPI Performance 2025/26 YTD |
|---|---|---|
| 6. We will grant, vary or refuse 95% of manufacturing and distribution authorisations within their category’s statutory timeline. | 95% | 95% |
| Regulatory Service | Target (days) | Last month average (days) | Notes |
|---|---|---|---|
| Wholesale Dealer Licences | Target timescales vary dependant on whether an inspection is required or not. | ||
| New Application | 90 | 77 | |
| Inspection | 90 | 36 | |
| No Inspection | 30 | 15 | |
| Manufacturing Licences | Target timescales vary dependant on whether an inspection is required or not. | ||
| New Application | 90 | 68 | |
| Inspection | 90 | 82 | |
| No Inspection | 30 | 14 |
Reports of Adverse Incidents
| Key Performance Indicator (KPI) | KPI Performance April 2025 | KPI Performance 2025/26 YTD |
|---|---|---|
| 7. We will process 90% of all UK initial spontaneous Reports of Adverse Incidents related to healthcare products within 24 hours. | 95% | 95% |
| Regulatory Service | Notes | |||
|---|---|---|---|---|
| Adverse Reaction Reviews (combined medicines and devices) | Register for safety alerts from MHRA. |
Scientific advice
| Key Performance Indicator (KPI) | KPI Performance April 2025 | KPI Performance 2025/26 YTD |
|---|---|---|
| 8. (a) We will offer scientific advice to 95% of requests within 70 days of the request being made. | 17% | 17% |
| (b) We will deliver the formal written advice for 95% of requests within 30 days of the meeting date or, if no meeting is required or requested, within 30 days of receiving company documentation. | 19% | 19% |
| Regulatory Service | Target (days) | Last month average (days) | Notes |
|---|---|---|---|
| Scientific Advice | Find out about our work to overhaul the Scientific Advice service at MHRA. |
(a) Meeting Date Offered
| Regulatory Service | Target (days) | Last month average (days) |
|---|---|---|
| Clinical Trials | 10 | 38 |
| New Active Substance | 10 | 42 |
| Population Health | 10 | 18 |
| Biologicals | 10 | 34 |
| PIQs | 10 | N/A |
(b) Written Advice Delivered
| Regulatory Service | Target (days) | Last month average (days) |
|---|---|---|
| Clinical Trials | 30 | 35 |
| New Active Substance | 30 | 48 |
| Population Health | 30 | 70 |
| Biologicals | 30 | 25 |
| PIQs | 30 | N/A |